Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author does not hold a position in RXRX.
← Back to Free Index

RXRX

Analysis as of: 2026-04-14
Recursion Pharmaceuticals, Inc.
Recursion is a clinical-stage biotech company that uses its Recursion OS platform, automated labs, and proprietary data to discover drug candidates for its own pipeline and for biopharma partners.
ai automation biotech healthcare software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Proof Could Unlock a Better Quality Multiple
The opportunity is real because the business owns data, labs, and compute rather than just AI software. The stock likely rerates only if that system keeps turning into credible human data, clearer regulatory paths, and more repeatable monetization.

Analysis

Thesis
At a cash-adjusted EV still dominated by proof risk, Recursion has a credible path to evolve from lumpy collaboration revenue into a higher-quality mix of product sales, milestones, royalties, and selectively externalized program vehicles if REC-4881 secures a workable regulatory path and at least one more platform-derived asset shows investable human data.
Last Economy Alignment
Recursion benefits from cheaper cognition because it owns data, automated labs, compute, and workflow integration rather than a thin software wrapper. The score stops short of higher levels because clinical proof and regulatory validation still decide whether that intelligence captures durable value.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
4.8x (from 5 most recent analyses)
Reasoning
The upside is a quality shift more than a pure volume story. If one internal asset reaches a credible approval path, a second program validates repeatability, and partner economics become more standardized, investors can value the company less like speculative discovery spend and more like a platform biotech that reliably mints assets and monetizes them several ways.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The core risk is not compute or liquidity today; it is proof and permissioning. If REC-4881 fails to secure a workable registration path, REC-1245 does not add a second credible translation signal, or partner monetization remains episodic, Recursion can stay trapped between platform promise and commercial reality. The offset is meaningful cash, real infrastructure, and multiple shots on goal.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.56
They control the data, lab machinery, and compute that can keep improving drug programs as AI gets cheaper, so the flywheel is real. The threat is that if trials and regulators do not keep validating the system, customers can treat it like another tool instead of a must-have engine.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$7.20
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case